Novak R.,Nabriva Therapeutics
Annals of the New York Academy of Sciences | Year: 2011
In 1951, the first reference to the antibacterial substance pleuromutilin was made in a paper published in theProceedings of the National Academy of Sciences. Researchers had identified several species of the mold genusPleurotusthat inhibited the growth ofStaphylococcus aureus. The elucidation of the structure in 1962 led to the initiation of a development program at Sandoz, which was followed by the approval of tiamulin in 1979 for use in veterinary medicine. Although in 2007 retapamulin became the first pleuromutilin approved for topical use in humans, it was not until 2011, exactly 60 years after the first mention of the class, that a pleuromutilin antibiotic, BC-3781, could be tested successfully in a clinical phase II trial for systemic use in patients. This review will discuss key aspects of this antibacterial class and provide some insight into the question of why it took half a century to develop a systemic pleuromutilin for human use. © 2011 New York Academy of Sciences.
Nabriva Therapeutics | Date: 2014-05-21
Pleuromutilin derivative compounds of the following formula, and uses thereof for the treatment of diseases mediated by microbes, are disclosed:
Nabriva Therapeutics | Date: 2010-08-12
The present invention relates to compounds of formula I and to compounds of formula II wherein the substituents have various meanings. These compounds are useful as beta lactamase inhibitors.
Nabriva Therapeutics | Date: 2011-05-23
Process for the preparation of a compound of formula I in the form of a single stereoisomer in crystalline form, comprising deprotecting the amine group in a compound of formula IIa or in a mixture of a compound of formula IIa with a compound of formula IIb and isolating a compound of formula I from the reaction mixture; compounds and salts of compounds of formula I in crystalline form; pharmaceutical compositions comprising such salts; processes for the preparation of intermediates and intermediates in a process for the preparation of a compound of formula I.
Nabriva Therapeutics | Date: 2011-10-25
A method of preventing or treating diseases caused by